| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.09 μM (5-lipoxygenase); 0.013 μM (12-lipoxygenase); 0.5 μM (15-lipoxygenase)[1].
2-TEDC primarily targets the lipoxygenase family of enzymes. It acts as a potent inhibitor with high potency against 5-LOX, 12-LOX, and 15-LOX. The compound's inhibitory effects on these enzymes are characterized by its ability to form stable complexes with the enzyme, altering its conformational dynamics. This broad inhibition of LOX pathways makes it useful for understanding the collective contribution of these pathways in disease models, such as atherosclerosis. |
|---|---|
| ln Vitro |
2-TEDC may effectively inhibit 5-, 12-, and 15-lipoxygenase with IC50 values of 0.09 μM, 0.013 μM, and 0.5 μM, respectively[1].
2-TEDC exhibits potent inhibitory activity against three lipoxygenase isoforms. Its IC50 values are 0.09 uM for 5-lipoxygenase (5-LOX), 0.013 uM for 12-lipoxygenase (12-LOX), and 0.5 uM for 15-lipoxygenase (15-LOX). These values demonstrate that 2-TEDC is most potent against 12-LOX. This broad spectrum of inhibition allows researchers to simultaneously block multiple branches of the arachidonic acid and linoleic acid metabolic pathways. |
| ln Vivo |
Published in vivo activity data for 2-TEDC is limited. Due to its ability to inhibit multiple pro-inflammatory LOX enzymes, it is suggested for research in disease models such as atherosclerosis, where all three LOX enzymes contribute to the pathology. By inhibiting these enzymes, 2-TEDC has the potential to reduce the formation of pro-inflammatory and pro-atherogenic lipid mediators. Further animal studies are required to establish its in vivo efficacy.
|
| Enzyme Assay |
The standard protocol for evaluating the inhibitory activity of 2-TEDC against LOX isoforms is through cell-free enzyme activity assays. Recombinant human 5-LOX, 12-LOX, or 15-LOX enzymes are incubated in an appropriate reaction buffer. Varying concentrations of 2-TEDC (e.g., 0.001-10 uM) are added, followed by the addition of the substrate (arachidonic acid for 5-LOX and 15-LOX; arachidonic acid or linoleic acid for 12-LOX). The reaction proceeds for a set time (e.g., 10-30 min) and is then terminated. The resulting products are quantified by HPLC or UV spectrophotometry to determine the IC50.
|
| Cell Assay |
For cell-based assays, cells such as human neutrophils (for 5-LOX) or platelets (for 12-LOX) can be pre-incubated with 2-TEDC at various concentrations. Cells are then stimulated with a calcium ionophore (e.g., A23187) to activate LOX pathways. Supernatants are collected to measure leukotriene B4 (from 5-LOX) or 12-HETE (from 12-LOX) by ELISA. Cytotoxicity is assessed via an LDH release assay to determine non-toxic concentration ranges.
|
| Animal Protocol |
A common in vivo model to study broad LOX inhibitors is the carrageenan-induced mouse paw edema model. 2-TEDC would be formulated in a suitable vehicle (e.g., 0.5% methylcellulose or 10% DMSO in saline) and administered orally or intraperitoneally at various doses (e.g., 10-100 mg/kg) to mice 1-2 hours before an intraplantar injection of carrageenan. Paw volume is measured over 4-6 hours using a plethysmometer to assess the anti-inflammatory effect. Blood or tissue samples can be collected to measure LOX products.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for 2-TEDC is limited. The compound has a molecular weight of 315.34 g/mol. As a potent small molecule, it is likely to have reasonable oral absorption. For in vivo formulation, it is typically dissolved in DMSO and then diluted in PEG300 or saline. Researchers should conduct pilot PK studies to determine parameters like plasma half-life, oral bioavailability, and tissue distribution for their specific animal model.
|
| Toxicity/Toxicokinetics |
Published toxicology data for 2-TEDC is not widely available. In vitro assays used to determine its IC50 values against LOX enzymes are typically conducted at concentrations that do not cause direct cytotoxicity. However, as with any potent inhibitor of key metabolic pathways, its safety profile would need to be thoroughly evaluated for any therapeutic application. For research use, standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
2-TEDC is a research-grade chemical tool and is not approved for clinical use. It is primarily used to study the role of lipoxygenases, and its broad-spectrum nature makes it a unique tool for elucidating the interplay between different LOX pathways, particularly in atherosclerosis research where it has been specifically mentioned. The compound should be stored as a powder at -20degC, protected from light and moisture. For research use only.
|
| Molecular Formula |
C16H13NO4S
|
|---|---|
| Molecular Weight |
315.34
|
| Exact Mass |
315.057
|
| CAS # |
132465-10-2
|
| PubChem CID |
6069552
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.852
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
470
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CSC(=C1)CCOC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N
|
| InChi Key |
KCGLTUBCAGZLHP-XYOKQWHBSA-N
|
| InChi Code |
InChI=1S/C16H13NO4S/c17-10-12(8-11-3-4-14(18)15(19)9-11)16(20)21-6-5-13-2-1-7-22-13/h1-4,7-9,18-19H,5-6H2/b12-8+
|
| Chemical Name |
2-thiophen-2-ylethyl (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (317.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1712 mL | 15.8559 mL | 31.7118 mL | |
| 5 mM | 0.6342 mL | 3.1712 mL | 6.3424 mL | |
| 10 mM | 0.3171 mL | 1.5856 mL | 3.1712 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
